Wyeth appealing two hormone verdicts

Another Prempro judgment, another appeal. An Arkansas jury yesterday ordered Wyeth and Upjohn to pay more than $27 million in punitive damages; that would allocate out to $19.4 million from Wyeth and $7.8 million from Upjohn, a Pfizer unit. That's on top of $2.75 million in compensatory damages. The jury found that the plaintiff developed breast cancer from taking the companies' hormone-replacement therapies.

By late afternoon, Wyeth had announced it plans to appeal the jury verdicts. "There is no basis in fact or law for this award...We will pursue several post-trial motions and will ultimately appeal the entire case if necessary," Wyeth's lawyer said.

Meanwhile, Wyeth is also appealing a Nevada court's ruling in a similar hormone-replacement case. A jury awarded three women $134 million in the case; though the judge then cut that award to $58 million, the company filed an appeal, saying that the verdict itself was "irreparably flawed and fraught with error." The company faces thousands of other hormone-replacement cases across the country.

- see the brief in the Wall Street Journal
- read the CNN Money report about the Arkansas appeal
- check out the Nevada coverage in the Reno Gazette-Journal

Related Articles:
Court dismisses lawsuit on Wyeth's Prempro. Report
Jury fines Wyeth $134.5M in hormone suit. Report
Wyeth asks judge to cut $134M award. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.